|
Press Releases |
|
|
|
Friday, April 13, 2018 |
|
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago |
Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the University of Chicago to develop a potential new treatment for tuberculosis (TB). more info >> |
|
Monday, April 2, 2018 |
|
Eisai Submits Supplemental New Drug Application to U.S. FDA |
Eisai Co., Ltd. has announced that it has submitted to the U.S. FDA a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) seeking approval for an indication expansion to cover pediatric patients with epilepsy. more info >> |
|
Wednesday, March 28, 2018 |
|
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement |
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical announced today that they have entered into a strategic alliance agreement as well as a share transfer agreement for a capital and business alliance. more info >> |
|
Friday, March 23, 2018 |
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal |
AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis. With this approval, HUMIRA has been approved for 10 indications in Japan. more info >> |
|
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA has been approved in Japan for unresectable hepatocellular carcinoma (HCC). more info >> |
|
Wednesday, March 14, 2018 |
|
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China |
Eisai Co., Ltd. announced today that its Chinese subsidiary Eisai China Inc. has launched the gastrointestinal prokinetic agent Cidine in China. more info >> |
|
Thursday, March 8, 2018 |
|
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai. more info >> |
|
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant |
Eisai Co., Ltd. and Purdue Pharma L.P. today announced positive topline results from multiple studies of lemborexant, an investigational agent for sleep and wake regulation currently being studied for the treatment of multiple sleep disorders. more info >> |
|
Tuesday, February 27, 2018 |
|
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan |
Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today. more info >> |
|
Wednesday, February 21, 2018 |
|
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500) |
Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
Turning Loss into Profit in 2023: IGG Achieved over HK$430 million in 2H23
Mar 28, 2024 14:25 HKT/SGT
|
|
|
Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan
Mar 28, 2024 13:52 JST
|
|
|
Toyota Releases Sales, Production, and Export Results for February 2024
Mar 28, 2024 13:35 JST
|
|
|
Steady Growth and Enhanced Value: Sunshine Insurance's 'New Sunshine Strategy' Sets Sail
Mar 28, 2024 12:33 HKT/SGT
|
|
|
Annual hiring demand declines 22% in Singapore: foundit Insights Tracker
Mar 28, 2024 11:10 HKT/SGT
|
|
|
Philippines Achieves Record-Breaking 18% Annual Surge in Hiring Activity for February 2024: foundit Insights Tracker
Mar 28, 2024 11:10 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports FY2023 Results
Mar 28, 2024 11:00 HKT/SGT
|
|
|
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 10:23 HKT/SGT
|
|
|
bluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities Violations
Mar 28, 2024 08:00 HKT/SGT
|
|
|
Grifols, S.A. (NASDAQ: GRFS) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. for Potential Securities Violations
Mar 28, 2024 08:00 HKT/SGT
|
|
|
TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants
Mar 28, 2024 3:00 JST
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|